NBO Pharma Inc. files Form D for $7 million private offering
The Delaware pharmaceutical company has sold $238,000 toward a $7 million equity and warrant offering as of a November 9, 2026 filing with the SEC.
NBO Pharma Inc., a Delaware corporation based in Bedford, New York, filed a Form D with the Securities and Exchange Commission dated November 9, 2026, disclosing a new private securities offering. The filing lists the date of first sale as November 2, 2026.1
The company is offering equity along with an option, warrant, or other right to acquire another security1, relying on Rule 506(c)1 of Regulation D.
According to the filing, the total offering amount is $7,000,000, with $238,000 sold so far and $6,762,000 remaining to be sold.1 Five investors have already put money into the offering.1 The minimum investment accepted from any outside investor is listed as $0.1
Paulson Investment Company, LLC, based in Portland, Oregon, is named as a sales compensation recipient. The issuer will provide the placement agent 13% of gross proceeds received from qualifying investors, a $50,000 expense fee, and 15% PA warrant coverage, with the commissions estimate assuming the full $7 million offering amount is sold to qualifying investors.1 Total sales commissions are listed at $960,000, with finders' fees at $0.1
The filing states the offering is not being made in connection with a business combination transaction such as a merger, acquisition, or exchange offer.1 The company also indicated it does not intend the offering to last more than one year.1
Related persons named in the filing include Fredric David Price, Robert Friedman, Colin Foster, and Bard Geesaman, all listed with addresses at the company's Bedford, New York location. The Form D was signed by Fredric D. Price, identified as Chief Executive Officer, on November 9, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.